Literature DB >> 29272899

Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease.

Ayesha Shah1,2,3, Erin Shanahan1,3, Graeme A Macdonald1,2,3, Linda Fletcher1,2, Pegah Ghasemi1,2, Mark Morrison1,4, Mike Jones5, Gerald Holtmann1,2,3.   

Abstract

The authors conducted a meta-analysis of the prevalence of small intestinal bacterial overgrowth (SIBO) in patients with chronic liver disease (CLD) and controls. Using the search terms "small intestinal bacterial overgrowth (SIBO)" and "chronic liver disease (CLD)" or "cirrhosis," 19 case-control studies were identified. Utilizing breath tests, the prevalence of SIBO in CLD was 35.80% (95% CI, 32.60-39.10) compared with 8.0% (95% CI, 5.70-11.00) in controls. Using culture techniques, the prevalence was 68.31% (95% CI, 59.62-76.00) in CLD patients as compared with 7.94% (95% CI, 3.44-12.73) in controls. No difference between cirrhotic and noncirrhotic patients was found. SIBO is significantly more frequent in CLD patients as compared with controls. The association of SIBO and CLD was not confined to patients with advanced CLD, suggesting that SIBO is not a consequence of advanced liver disease but may play a role in the progression of CLD. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2017        PMID: 29272899     DOI: 10.1055/s-0037-1608832

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  21 in total

1.  Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis?

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Turk J Gastroenterol       Date:  2019-11       Impact factor: 1.852

Review 2.  Gastroduodenal "Dysbiosis": a New Clinical Entity.

Authors:  Ayesha Shah; Mark Morrison; Gerald J Holtmann
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

3.  Small intestinal bacterial overgrowth in inflammatory bowel disease.

Authors:  Ayesha Shah; Gerald Holtmann
Journal:  Indian J Gastroenterol       Date:  2022-01-15

Review 4.  Cirrhosis-associated immune dysfunction.

Authors:  Agustín Albillos; Rosa Martin-Mateos; Schalk Van der Merwe; Reiner Wiest; Rajiv Jalan; Melchor Álvarez-Mon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-26       Impact factor: 46.802

Review 5.  Gut Barrier and Microbiota in Cirrhosis.

Authors:  Cyriac A Philips; Philip Augustine
Journal:  J Clin Exp Hepatol       Date:  2021-09-03

6.  Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Hepatol Int       Date:  2018-10-04       Impact factor: 6.047

Review 7.  The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis.

Authors:  Maruhen A D Silveira; Steve Bilodeau; Tim F Greten; Xin Wei Wang; Giorgio Trinchieri
Journal:  Trends Cancer       Date:  2022-03-21

Review 8.  Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.

Authors:  Daniela Campion; Ilaria Giovo; Paola Ponzo; Giorgio M Saracco; Federico Balzola; Carlo Alessandria
Journal:  World J Hepatol       Date:  2019-06-27

Review 9.  The Role of the Microbiome in Liver Cancer.

Authors:  Mar Moreno-Gonzalez; Naiara Beraza
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

Review 10.  Gut⁻Liver Axis: How Do Gut Bacteria Influence the Liver?

Authors:  Peter Christopher Konturek; Igor Alexander Harsch; Kathrin Konturek; Monic Schink; Thomas Konturek; Markus F Neurath; Yurdaguel Zopf
Journal:  Med Sci (Basel)       Date:  2018-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.